Mainz Biomed NV
MYNZ
View Detailed Chart
1.610USD
-0.040-2.42%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
3.73MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.42%
5 Days
-3.01%
1 Month
-10.56%
6 Months
-62.30%
Year to Date
-62.73%
1 Year
-83.89%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance, the company shows weak fundamentals and technicals, which don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
14.000
Target Price
+748.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 68.72% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 893.99K.
Overvalued
The company’s latest PE is -0.07, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 323.69K shares, decreasing 1.36% quarter-over-quarter.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Ticker SymbolMYNZ
CompanyMainz Biomed NV
CEOMr. Guido Baechler
Websitehttps://www.mainzbiomed.com/
Related Instruments
+0.31%
+0.67%
+0.69%
+0.04%
+0.15%
-0.08%
+2.88%
-1.01%
+0.28%
-0.05%
-1.66%
-0.63%
-1.31%
-0.18%
+0.22%
-0.35%
-2.13%
-4.24%
-0.85%
0.00%
